| 초록 |
Various anticancer agents are used in cancer therapy. But, tumor drug resistance is a hurdle in cancer therapy. Bevacizumab is a therapeutic antibody neutralizing VEGF to suppress the tumor growth. But, it has side effects limiting its therapeutic efficacy. In this study, small interfering RNA (siRNA) targeting VEGF was delivered to bevacizumab resistant tumors. Polymerized siRNA (poly-siRNA) was encapsulated in tGC nanoparticles (Psi-tGC). PsiVEGF-tGC induced gene silencing in both bevacizumab sensitive and resistant cell lines in vitro. PsiVEGF-tGC suppressed the tumor growth in both cell lines without drug resistance compared to bevacizumab in vivo. Bevacizumab is an agent binding to VEGF, but mutation of binding site of VEGF and existence of isoforms can lower the therapeutic efficacy. But, RNAi is a sequence-specific mechanism to regulate the protein expression. Thus, therapeutic RNAi with tumor-targeting ability is an alternative to overcome the limitation of cancer therapy. |
